VantAI Enters Collaboration With Bristol Myers Squibb to Accelerate Molecular Glue Drug Discovery Through Artificial Intelligence
NEW YORK--(BUSINESS WIRE)--VantAI, a company focused on generative AI-enabled drug discovery, and Bristol Myers Squibb (NYSE: BMY), a leading pharmaceutical company, have entered into a strategic collaboration to discover new molecular glues for therapeutic targets of interest. The partnership leverages VantAI's geometric deep learning capabilities with Bristol Myers Squibb’s expertise in targeted protein degradation to discover and develop new small molecule therapeutics. The collaboration will focus on ...